Liposomal Cytarabine and Daunorubicin (CPX-351) for Adults With Untreated High-Risk MDS and Non-APL AML at High Risk of Treatment-Related Mortality

Trial Profile

Liposomal Cytarabine and Daunorubicin (CPX-351) for Adults With Untreated High-Risk MDS and Non-APL AML at High Risk of Treatment-Related Mortality

Completed
Phase of Trial: Phase III

Latest Information Update: 30 May 2018

At a glance

  • Drugs Cytarabine/daunorubicin (Primary)
  • Indications Acute biphenotypic leukaemia; Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Apr 2018 Status changed from active, no longer recruiting to completed.
    • 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
    • 11 Jan 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top